India's pharmaceutical industry is evolving. What began as generics manufacturing — making the world's medicines affordable — is becoming research-driven innovation.
India's pharmaceutical patent filings have surged from 7,158 in 2014 to 18,668 in 2024 — a 160% increase in a decade. This is not incremental growth. It signals a structural shift in what India's pharmaceutical industry aspires to be.
India's pharmaceutical exports have grown from $14 billion to $31 billion in twelve years. Industry and government targets point toward $50 billion. Getting there will require not just volume, but value — novel molecules, biosimilars, and therapies developed from Indian soil.
The generics foundation remains essential: affordable medicine for the world. But the next chapter adds invention on top of access.